• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sims Andrew John Hugh Macintyre bought $10,000 worth of shares (4,902 units at $2.04), increasing direct ownership by 601% to 5,717 units (SEC Form 4)

    5/10/24 7:30:19 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care
    Get the next $PSTV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Sims Andrew John Hugh MacIntyre

    (Last) (First) (Middle)
    C/O PLUS THERAPEUTICS INC.
    4200 MARATHON BOULEVARD, SUITE 200

    (Street)
    AUSTIN TX 78756

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PLUS THERAPEUTICS, INC. [ PSTV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/08/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/08/2024 P 4,902 A $2.04 5,717 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrants (Right to buy) $1.79 05/08/2024 A 9,804 05/08/2024 (1) Common Stock Warrants(2) 9,804 $0 9,804 D
    Explanation of Responses:
    1. The expiration date for 4,902 of the warrants (Series A warrants) is May 8, 2029. The expiration date for the other 4,902 warrants (Series B warrants) is the one-year anniversary of the effectiveness of a registration statement covering the resale of shares of common stock underlying the Series B warrants.
    2. Half of the warrants are Series A warrants and the other half are Series B warrants.
    /s/ Andrew Sims 05/10/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PSTV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PSTV

    DatePrice TargetRatingAnalyst
    3/17/2025$9.00Buy
    D. Boral Capital
    More analyst ratings

    $PSTV
    SEC Filings

    See more
    • SEC Form PRE 14A filed by PLUS THERAPEUTICS Inc.

      PRE 14A - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      7/11/25 4:06:44 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by PLUS THERAPEUTICS Inc.

      EFFECT - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      6/24/25 12:15:25 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form RW filed by PLUS THERAPEUTICS Inc.

      RW - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      6/23/25 4:15:11 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

      The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases Presentations will highlight the clinical utility of the company's CNSide Cerebrospinal Fluid (CSF) Assay Platform for patients at risk for central nervous system metastases HOUSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that its wholly-owned subsidiary, CNSide Diagnostics, LLC ("CNSide") will be sh

      7/10/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

      HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the treatment of its initial patients in the Company's ReSPECT-LM dose optimization trial for REYOBIQTM (rhenium Re186 obisbemeda) for the treatment of leptomeningeal metastases (LM). The dose optimization trial builds on promising results from the Company's completed Phase 1 single-dose escalation study, which demonstrated the feasibility of REYOBIQ for treating LM. The trial is designed in alignment with the FDA's Project

      7/8/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

      Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award from the Cancer Prevention & Research Institute of Texas HOUSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the initiation of the ReSPECT-LM dose optimization trial for REYOBIQTM (rhenium Re186 obisbemeda) for the treatment of leptomeningeal metastases (LM). The dose optimi

      6/30/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Clowes Howard

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:10 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Hawkins Richard J

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:11 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Petersen Greg

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:03 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/17/24 7:00:04 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Director Hawkins Richard J bought $8,512 worth of shares (6,285 units at $1.35), increasing direct ownership by 128% to 11,188 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/16/24 7:00:03 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Director Petersen Greg bought $16,875 worth of shares (12,500 units at $1.35), increasing direct ownership by 34% to 48,921 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/13/24 6:04:12 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Plus Therapeutics with a new price target

      D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00

      3/17/25 7:41:57 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • HC Wainwright initiated coverage on Plus Therapeutics

      HC Wainwright initiated coverage of Plus Therapeutics with a rating of Buy

      2/11/21 7:44:56 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. initiated coverage on Plus Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $7.00

      2/11/21 6:52:36 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Financials

    Live finance-specific insights

    See more
    • Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

      U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a conference call today at 9am ET HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will provide a business update for its wholly-owned subsidiary, CNSide Diagnostics, LLC ("CNSide"). The proprietary CNSide Cerebrospinal Fluid (CSF) Assay Platform is designed and intended for patients s

      6/26/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

      HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, June 26, 2025 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call  Date/Time:Thursday, June 26, 2025 @ 9:00 AM ET Webcast: https://edge.media-server.com/mmc/p/97egitn8 Dial-in Link: https://register-conf.media-server.com/re

      6/25/25 4:15:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights. "Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "The rece

      3/27/25 4:05:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

      HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his

      4/23/25 8:00:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

      AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer. Dr. Rosol will lead the company's clinical, pre-clinical, and biomarker development activities. "Plus is at an inflection point in our clinical development as we move from mid-stage to pivotal trials next year," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Mike's background in oncology and radiotherapeutic

      2/20/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

      Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Dr. Greg Fuller a

      6/7/24 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

      SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      6/5/24 7:26:01 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

      SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      2/13/23 3:25:03 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

      SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      2/11/22 7:53:23 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care